gland pharma promoters

It is majority-owned by Fosun International. Cr.) Pally, Dundigal Gandimaisamma Mandal Medchal-Malkajgiri District Hyderabad 500043, Telangana, India Phone: +91-40-30510999 Fax: +91-40-30510800 Email: gland@glandpharma.com Promoters of Hyderabad-based speciality injectable drugs maker Gland Pharma have decided to put their controlling stake on the block. Business. Gland Pharma has fixed a price band of Rs 1,490-1,500 per share for the IPO. Gland Pharma is set to be India’s largest pharma public offering, with an issue size of Rs. What should investors do with this IPO – should they put money in it or skip it? Gland Pharma Ltd(GPL) was incorporated in the year 1978 in Hyderabad by PVN Raju and later scaled up by his son Ravi Penmetsa. Chemcon Speciality Chemicals (Chemcon) IPO: Key things you must know! Gland Pharma promoters put their 60 per cent stake on the block 20 Aug, 2015, 04.00 AM IST Promoters of Hyderabad-based speciality injectable drugs maker Gland Pharma have decided to put their controlling stake on the block. It sells its products primarily under a business to business (“B2B”) model in over 60 countries as of March 31, 2020, including the United States, Europe, Canada, Australia, India and the Rest of the world. List of Related Parties (Key Managerial Personnel) Srinivas Sadu, MD and CEO; Ravi Shekhar Mitra, Chief Financial Officer; K V G K Raju, Chief Technology Officer; P. Sampath Kumar, Company Secretary and Compliance Officer ; Interest in … Gland Pharma gets Sebi approval for Rs 6,500-crore IPO, set for first listing of an Indian firm with a Chinese parent. Gland Pharma total market cap rose to ₹28,636.54 crore at 10:03 am. Price range for the IPO was fixed at Rs 1,490-1,500 per share. 41459; Add/Edit Companies . Chinese drug firm Fosun Pharma has acquired approximately 74 per cent in Hyderabad-based Gland Pharma at a valuation of not more than USD … Gland Pharma is primarily a Generic Injectables company and its largest promoter is Chinese Pharmaceutical giant, Shanghai Fosun Pharma. In any case, one can say that the P/E scope is high, considering its scope from 30x to 39x. Established in Hyderabad, India in 1978, Gland Pharma has grown to become one of the biggest and quickest developing injectable-centered organizations. The company will become the first large Indian firm with a Chinese parent to go for public listing. Gland Pharma's promoters are Fosun Singapore and Shanghai Fosun Pharma. The primary market includes putting resources into the stock market by applying to the Initial Public Offering (IPO) of an organization while the auxiliary or secondary market includes buying and selling shares directly from the stock trade. The Benchmarking section has been moved to the next tab. Currently, the promoters of the company are Fosun Singapore which is own by (Shanghai Fosun Pharma). Presently, because of the COVID-19 pandemic, there is a global anti-China wave. Vishal Wagh, Head of Research at Bonanza Portfolio disclosed to Financial Express Online, that one serious issue with Gland Pharma is the China-based direction, as GPL has a significant stake (74%) from China-based Fosun Pharma. Vishal Wagh, Head of Research at Bonanza Portfolio disclosed to Financial Express Online, that one serious issue with Gland Pharma is the China-based direction, as GPL has a significant … This means that the organization is soliciting the issue cost from Rs 1,500 of the upper-value band in the P/E scope of 30x to 39.3x. The organization has a portfolio of injectable items across different helpful areas and delivery systems. here . PRINT Balance Sheet Standalone; Consolidated; View Detailed (in Rs. The table below lists out the details of the shareholding pattern prior to the Gland Pharma IPO. Manufacturing or quality control issues may upset the pharma business, harm organization notoriety, and uncover possible suits or liabilities which could affect the business. Gland Pharma Ltd is a Public incorporated on 20 March 1978. 154,949,488. Gland Pharma IPO Promoter Holding. 5. A new variant of coronavirus has been found which is growing faster in some parts of England, British MPs have been told. Price. Promoters of Hyderabad-based speciality injectable drugs maker Gland Pharma have decided to put their controlling stake on the block. Gland Pharma IPO – Should you invest? Increase current market presence and enter new business sectors. Its margins have improved year on year in the last 3 years. Gland Pharma IPO: The issue will close on November 11 Gland Pharma’s ₹ 6,480-cr IPO off to a slow start 1 min read. Updated: 09 Nov 2020, 10:22 PM IST Ashwin Ramarathinam. “Company coming … It has been consistent in its performance with strong fundamentals. Gland Pharma Initial Public Offering (IPO) opened today. The remaining shares are of Empower Discretionary Trust and Nilay Discretionary Trust. Align with Shanghai Fosun Pharma to expand a piece of the overall industry. COVID-19 is a threat as supply disruptions have occurred. Gland Pharma IPO Subscription Details: Institutional investors: 3.05x; High net-worth individuals: 9% ; Retail investors: 18%; The injectables maker plans to raise Rs 6,480 crore through the maiden offer at Rs 1,490-1,500 apiece. Gland Pharma’s public issue consisted of a fresh issue of Rs 1,250 crore and an offer for sale of over 3.48 crore equity shares. Its products are offered to 60+ nations over the world. Gland Pharma IPO lacked confidence from investors as the company only secured 4 per cent of subscription on the first day. The IPO consists of a fresh issue of Rs 1,250 crore and an offer for sale of 3,48,63,635 equity shares by the promoter and other selling shareholders. The company's promoters are Fosun Singapore and Shanghai Fosun Pharma. It includes the shares of both promoters and selling shareholders. Scope of growth as the pharma sector is growing globally as they make complex injectables. The offer comprised issuance of fresh shares worth up to Rs 1,250 crore and an offer for sale (OFS) of up to 3,48,63,635 shares. As you can see from the financial records, Gland Pharma has posted strong growth in revenues over the last three years. Hyderabad-based injectable-focus-med drugmaker Gland Pharma opened its public issue for subscription on November 9 at Rs 1,490-1,500 per share with the issue band. "In this way, there is a vulnerability about the near term future. The offer comprised issuance of fresh shares worth up to Rs 1,250 crore and an offer for sale (OFS) of up to 3,48,63,635 shares. Its authorized share capital is Rs. Gland Pharma Initial Public Offering (IPO) opened today. - Promoters in the company - Fosun Singapore and Shanghai Fosun Pharma - will reduce their shareholding from 74% to around 58 percent. There are no recorded peers who are doing similar business; consequently, one can't discover whether the issue cost is undervalued or overrated. Will Invest or let go? 6,480 crore IPO on Monday 9 th November 2020, 20% of which, comprises fresh issue of Rs. Ravi Penmetsa and family, which controls 60% of Gland Pharma, have mandated investment bank Jefferies & Co to look for buyers, these people said, adding that they are expecting an enterprise valuation of $1-1.2 billion (Rs 6,400-7,680 crore). SEBI’s New Margin System for Non-F&O Stocks. Gland Pharma plans to raise ₹1,250 crore through the IPO. 6,479.5 crores. With Initial Public Offering, the organization gets its shares listed on the stock exchange. We use cookies to ensure the best experience for you on our website.If you choose to ignore this message, we'll assume that you are happy to receive all cookies on ET HealthWorld. All Rights Reserved. 2) Expansion into Various Geographies. Scientists develop new inhalation delivery system for vaccines, Serum to file Rs 100 crore case after man’s vaccine trial distress claim, WHO says more data needed on AstraZeneca dose, Court rejects AstraZeneca’s plea on diabetes drug patent, AI is playing a major role in precision medicine for targeted disease management: Rajashree Damle, Capgemini, Neonatal hypoglycemia, genetic diseases are underlying cause of epilepsy in young Indian children, says study, COPD patients are at greater risk of developing severe Covid-19 disease: Dr Sundeep Salvi, Director, PURE Foundation, Narayana Health, Mazumdar Shaw Medical Foundation launches MSMF MedTech Innovation Centre in Bangalore, We need traditional meditative practice to restore normalcy to our sleeping patterns: Dr. Jayaram Thimmapuram, WellSpan York Hospital, York, Telemedicine can provide timely access and last mile connectivity for peri-urban and rural populations: Santanu Mishra, Smile Foundation, NATHEALTH and the Africa Health Federation will work together to make UHC a reality: Preetha Reddy, Vice Chairperson, Apollo Hospitals, Non-Contact Thermometers (Infrared Guns) Miss 5 Out of 6 Fevers: Reveals Study, OptraLABS receives ICMR nod for its Covid-19 recovery test kits, WHO pre-qualifies Biological E’s typhoid conjugate vaccine, Embed ETHealthworld.com Widgets on your Website. The organization announcing or doing it may be a new or an old organization. Research data on Gland Pharma such as Market Share, Product, Geography & Annual Report Summary. About Gland Pharma Limited IPO. Financial. It is smarter to keep away from it specifically when the second wave of Covid has already started in many nations," Wagh added. She can be found researching, exercising, and binging to balance life. It offers its products through a business-to-business (B2B) model across 60 nations over the globe (as of June 30, 2020), which include the United States, Europe, Canada, Australia, India and other markets. Before the price band declaration, Gland Pharma shares were trading with almost Rs 200 premium in the grey market, which has now fallen to Rs 65 per share over the issue price of Rs 1500. Numerous nations are taking majors to boycott China. High Concentration of revenues from the US. The company business is dependent on the sale of products in 60+ nations through its key clients and key business sectors. We have various options to advertise with us including Events, Advertorials, Banners, Mailers, Webinars etc. Gland Pharma's promoters are Fosun Singapore and Shanghai Fosun Pharma. From being investors bringing in growth capital, private equity (PE) firms are now getting into the promoter seat of Indian pharmaceutical and healthcare companies. Gland Pharma shares received an overwhelming response from investors on their first day on Friday as they rose up 23 per cent when compared to the issue price of Rs 1,500. Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. Pfizer’s COVID vaccine and allergies: How concerned should you be? Please review and accept these changes below to continue using the website.You can see our privacy policy & our cookie policy. The IPO is a mixture of primary and secondary issue of shares with both China’s Fosun group and the founders of Gland Pharma due to dilute shares. |, Top 10 Indian Merger and Acquisition Deals, Ketan Parekh scam: All that you must know, All About Pradhan Mantri Awas Yojana [PMAY –urban], IPO allotment Process: Know all about Allotment of Shares, IPO vs OFS: Difference between IPO, FPO and OFS, IPO Process: 5 steps for Successful Listing. WEB The table below summarizes the key financial figures of Gland Pharma from 2017 to 2020. Also read: China’s Fosun Kicks Off Biggest Pharma IPO in India 1,250 crores and an offer for sale (OFS) of 3.4 crore equity shares by the promoters and other selling shareholders. One of the promoters in Gland Pharma is Shanghai Fosun Pharmaceutical Co., Ltd., known as Fosun Pharmaceutical or just Fosun Pharma is a Chinese listed pharmaceutical company. Copyright © 2020 ETHealthworld.com. 1,490-1,500 per share. It has posted strong revenue growth in the last 3 years. Any loss of such clients can bring about a decrease in deals and further affect organization edges. Gland Pharma now has a market cap of Rs 29,724.82 crore, which places it among the top ten pharma stocks. Subsequently the name of the Company was changed to `Gland Pharma Limited' pursuant to a special resolution passed by the shareholders of the Company … FRIENDS. Gland Pharma IPO will be India's largest pharma IPO in the history. Out of the total shares, 1.9 crore shares are of Fosun Pharma Industrial Pte and one crore shares are of Gland Celsus Bio Chemicals. The company is coming up with 1250 crore fresh issue and 5229 crores of offer for sale. It has a presence in sterile injectables, oncology, and ophthalmics, and centres around complex injectables, NCE-1s, First-to-File items, and 505(b) (2) filings. 2200.00-24.40 (-1.10%) Benchmarking. Gland Pharma has seven manufacturing offices in India, containing four completed formulations facilities with a sum of 22 production lines and three API facilities. The organization has posted solid revenue gain over the most recent 3 years. Pre Issue Share Holding: 74%: Post Issue Share Holding: 58%: Related Articles. For the most recent 3 years, normal EPS of Rs 38.11, the PE proportion is 39.3x. IPO stands for Initial Public Offering. The offer comprises a fresh issue of equity shares worth Rs 1,250 crore, and a sale of 3.5 crore shares by promoters and other investors. Zee Business Managing Editor Anil Singhvi gives his sharp and incisive take on it! The company has grown from being contract manufacturer of small volume liquid parenteral products to become one of the largest … 6,480 crore IPO on Monday 9 th November 2020, 20% of which, comprises fresh issue of Rs. Replying to a query on the several restrictions being imposed by the Centre on Chinese companies, Sadhu said they don't foresee any issues as Gland Pharma is in the healthcare sector. Reply. Vertically integrated injectables manufacturing capability. 563,000,000 and its paid up capital is Rs. The offer comprised issuance of fresh shares worth up to Rs 1,250 crore and an offer for sale (OFS) of up to 3,48,63,635 shares. The company’s promoters are Fosun Singapore and Shanghai Fosun Pharma. 0 ⭐⭐⭐⭐⭐ Most Influential Member (2947 Posts) Balance Sheet Analysis: 1. The IPO is broken down into a fresh issue of 83 lakh shares amounting to Rs. Please click . Gland Pharma is one of the fastest growing generic injectables-focused companies by revenue in the United States from 2014 to 2019 (Source: IQVIA Report). Gland Pharma is promoted by Fosun Singapore and Shanghai Fosun Pharma. LTD; SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. Gland Pharma launch the IPO in … Existing promoters plan to sell around 34 million shares, which could be worth around ₹4,750 crore. One of the promoters in Gland Pharma is Shanghai Fosun Pharmaceutical Co., Ltd., known as Fosun Pharmaceutical or just Fosun Pharma is a Chinese listed pharmaceutical company. If such courses of action are ended for any reason, it would affect the organization's business. Click "Continue" to accept and continue with ET HealthWorld. Gland Pharma IPO details includes issue size, issue price, discount information, minimum and maximum order quantity, promoters holding details, NSE and BSE code. The promoters of Gland Pharma Ltd: FOSUN PHARMA INDUSTRIAL PTE. MUMBAI: Promoters of Hyderabad-based speciality injectable drugs maker Gland Pharma have decided to put their controlling stake on the block, three people with direct knowledge of the matter said. Copyright © 2020 Finology Ventures Pvt. GLAND PHARMA IPO Must know Facts | IPO DATE PRICE | GLAND PHARMA IPO PROMOTERS | GLAND PHARMA NEWS ----- How to apply for IPO ? It manufactures a diversified range of high-quality complex injectables. Promoters of Gland Pharma IPO. Its IPO issue price is highly priced. Most brokerage houses have a bullish view on Gland Pharma and have assigned a 'Subscribe' rating to the issue. A total traded quantity of 1.39 lakh shares changed hands on BSE amounting to a turnover of ₹23.86 crore. Leverage high entry barriers by diversifying their portfolios and make new delivery systems. "With a solid item pipeline and more unpredictable items being worked on, centre around B2B development and authorizing and occasions to enter more treatment territories, the offer looks appealing," it added. Through the IPO, the company plans to raise close to Rs 6,500 crore, which is the largest IPO in the pharma sector. Gland Pharma is a business-to-business (B2B) player in the fast-growing global (particularly the US) generic injectables space, within the otherwise highly competitive generics market. Company API creation interference could affect its deals. Gland Pharma was founded by P V N Raju in 1978 and Fosun Pharma acquired 74% stake in the company in 2017. Gland Pharma promoters put their 60 per cent stake on the block MUMBAI: Promoters of Hyderabad-based speciality injectable drugs maker Gland Pharma have decided to put their controlling stake on the block, three people with direct knowledge of the matter said. The company’s promoters are Fosun Singapore and Shanghai Fosun Pharma. This company was started by PVN Raju, but there is a catch. Reply. Get ETHealthworld's top stories every morning in your email inbox. A total traded quantity of 1.39 lakh shares changed hands on BSE amounting to a turnover of ₹23.86 crore. Gland Pharma Ltd was incorporated as `Gland Pharma Private Limited' a private limited company under the Companies Act 1956 on March 20 1978 and was granted the certificate of incorporation by Registrar of Companies Andhra Pradesh at Hyderabad. Mrs. Bector's Food IPO: Should you Subscribe? It is majority-owned by Fosun International. The Pharma industry is intensely managed, and business organizations require a few endorsements, licenses, enrollment, and consents. 1,490-1,500 per share. Market Wizard. The public issue 0.24x in the retail category, … Dear user, ET HealthWorld privacy and cookie policy has been updated to align with the new data regulations in European Union. Gland Pharma open for subscription; why should you subscribe? So, what’s going to be your call? LTD & SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. Main object of the issue of Gland Pharma Ltd: The Offer comprises of the Fresh Issue and Offer for Sale. Gland Pharma, a Hyderabad-based ... November 9 to 11, comprises a fresh issue of up to ₹1,250 crore and a 22.5 per cent offer for sale by the company’s promoters and other shareholders. Also, if we look at the profits, they have increased in 2019 and 2020 by 40.74% and 71.04% respectively, which suggests that the company looks after cost optimization. The stock market is one of the most rewarding investment plans in India. The Promoter of this company is: FOSUN PHARMA INDUSTRIAL PTE. Covid-19 recovery rate in India among highest in the world: Health Ministry54 mins ago, HC notice to Centre on plea against allowing non-medical persons to certify diagnostic reports4 hrs ago. She finds her happy place in writing. 1,250 crore and 80% an offer for sale (OFS) of up to 3.49 crore equity shares of Re.1 each, almost equally by Chinese promoter Fosun Pharma and company’s original Hyderabad-based founding family, in the price band of Rs. This will be updated shortly! Pursue key acquisitions and associations. Gland Pharma is launching a Rs. Gland Pharma now has a market cap of Rs 29,724.82 crore, which places it among the top ten pharma stocks. Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. Fosun Pharma will sell a 12.5% stake. It is producing significant and improved products over the most recent 3 years. Financial Overview of Gland Pharma IPO . Gland Pharma gets Sebi approval for Rs 6,500-crore IPO, set for first listing of an Indian firm with a Chinese parent. Gland Pharma Ltd.’s initial public offering witnessed a healthy response on the final day of bidding. The company offers products like sterile injectables, oncology, and ophthalmics, complex injectables (peptides, suspensions, hormonal products, long-acting injectables), NCE-1s, First-to-File products, etc. Gland Pharma launch the IPO in … It … We have updated our terms and conditions and privacy policy What should investors do with this IPO – should they put money in it or skip it? Gland Pharma Ltd. Data for this company is currently being indexed. Dependence on China for the supply of raw materials. The Company proposes to utilise the Net Proceeds towards funding of the following main objects: 1. These firms are not related to Gland Pharma or its promoters, promoter group, directors or key managerial personnel, the company said in its IPO prospectus. Gland Pharma is one of the fastest growing generic injectable companies in India. On the upper-value band of Rs 1,500 and EPS of Rs 49.88 for FY20, the P/E proportion works out to be 30x. The issue was subscribed 98% as of 1:00 pm on Nov. 11, led by institutional investors who bid for three times the shares on offer. The company's promoters are Fosun Singapore and Shanghai Fosun Pharma. An organization's prosperity relies significantly upon the business’s courses of action with its advertising accomplices and clients for the offer of its items. The company is now a public limited company. Promoter Shareholding Pattern . Gland Pharma is launching a Rs. Equitas Small Finance Bank IPO: Key things! It has a history of working a B2B model with some driving pharma groups like Sagent Pharmaceuticals Inc., Apotex Inc., Fresenius Kabi USA LLC, Athenex Pharmaceutical Division LLC (US), and more. About Gland Pharma Limited IPO. Zee Business Managing Editor Anil Singhvi gives his sharp and incisive take on it! Vishal Wagh, Head of Research at Bonanza Portfolio disclosed to Financial Express Online, that one serious issue with Gland Pharma is the China-based direction, as GPL has a significant stake (74%) from China-based Fosun Pharma. Follow @ETHealthworld for the latest news, insider access to events and more. Gland Pharma total market cap rose to ₹28,636.54 crore at 10:03 am. In 2017, Shanghai-based Fosun Pharma acquired a 74% stake for over $1.2 Bn. Financial Overview of Gland Pharma IPO . Ltd. | All Rights Reserved, Ishita Jha Gland Pharma is one of the fastest growing generic injectables-focused companies by revenue in the United States from 2014 to 2019 . It is classified as Non-govt company and is registered at Registrar of Companies, Hyderabad. Fresh issue: Company is putting together the new issue of offers and would use the returns for the accompanying: Expand product portfolio and delivery frameworks to drive income growth. This comes at a time when India and China engaged in a face-off at the Line of Actual Control, following which the Central government took retaliatory economic and trade measures … The figures below are in Rs. Company was established in Hyderabad, India in 1978 and has a professional management team and one of our Promoters, Shanghai Fosun Pharma, is a global pharmaceutical major. Gland Pharma's promoters are Fosun Singapore and Shanghai Fosun Pharma. Gland Pharma IPO is open till Wednesday and the investors will be able to do a minimum investment of Rs 15,000. Gland Pharma IPO - Subscribe Says Research Analysts ; Gland Pharma IPO opens on 9th November 2020; Gland Pharma IPO Subscription Status (Bidding Detail) The Burger King IPO is subscribed 12x times on Nov 11, 2020 18:00. Fosun Singapore; Shanghai Fosun Pharma; Summing Up. Gland pharma’s promoter is a global Pharmaceutical giant having global presence, and its always better for any company to have a Strong backing and that too if its from a global giant then its too good for the Company. Gland Pharma Ltd was incorporated as `Gland Pharma Private Limited' a private limited company under the Companies Act 1956 on March 20 1978 and was granted the certificate of incorporation by Registrar of Companies Andhra Pradesh at Hyderabad. Gland Pharma IPO is open till Wednesday and the investors will be able to do a minimum investment of Rs 15,000. As we can see, from 2018 to 2019, there is an increase of 27.4% in the total income. Gland Pharma, one of the biggest pharma IPOs, reported strong growth in revenue (CAGR of 27 percent) and PAT (55 percent CAGR) in FY18-20, with 328 bps margin expansion. Gland Pharma Ltd is a generic injectables-focused company and sell the products primarily under a business to business (“B2B”) model in over 60 countries. Funding incremental working capital requirements of … Gland Pharma will launch its maiden public offer on November 9, which consists a fresh issue of Rs 1,250 crore and an offer for sale of over 3.48 crore shares by promoters and others. Gland Pharma IPO – Promoters. Today we will attempt to understand the company’s structure and business model, followed by an intrinsic and relative valuation. In 2020, there is a 30.17% growth in revenues. The IPO is a mixture of primary and secondary issue of shares with both China’s Fosun group and the founders of Gland Pharma due to dilute shares. The company is a manufacturer, marketer, and developer of complex injectables across its seven manufacturing facilities. Gland Pharma Limited Survey No. The company’s share in the intraday trade so far has hit a high of Rs 1,850 on the BSE. Gland Pharma is primarily a Generic Injectables company and its largest promoter is Chinese Pharmaceutical giant, Shanghai Fosun Pharma. Despite what might be expected, research firm GEPL Capital has prescribed a 'buy-in' to the issue as it is evaluated at P/E of 18.52x on annualized EPS of the quarter finished June 2020. 0 The company was incorporated in 1978 based in Hyderabad. Mumbai: China’s Fosun Pharma is planning an initial public offering for its Indian subsidiary Gland Pharma, which could be the first Indian company with a Chinese promoter to make a debut on Dalal Street. It sells its products primarily under a business to business (“B2B”) model in over 60 countries as of March 31, 2020, including the United States, Europe, Canada, Australia, India and the Rest of the world. Gland Pharma Ltd, the Hyderabad-based company is one of the fastest-growing generic injectable companies. Chinese promoters are a problem due to border tension. Investors trade in the stock market either through the primary market or through the secondary market. August 30, 2020 10:45 am. While pharmaceutical major Pfizer had made headlines on the release of their Covid-19 vaccine, its former Vice President and Chief Scientist has said that there is no need for any vaccines to bring the pandemic to an end. Today we will attempt to understand the company’s structure and business model, followed by an intrinsic and relative valuation. Other metrics include Any change in such guidelines can postpone the endorsements and can affect the performance and income of the organization. Promoter Shareholding Pattern . Individuals put resources into the stock market since it can possibly produce attractive returns in a little range of time. This shows how robust the company is. Gland Pharma Ltd.’s three-day initial public offer opens on Nov. 9 as the China’s Sanghai Fosun-controlled injectables maker sells shares in what will be the biggest maiden offer by a pharmaceutical company in India.. Covid-19 recovery rate in India among highest in the world: Health Ministry, HC notice to Centre on plea against allowing non-medical persons to certify diagnostic reports, With 24,010 new Covid-19 cases, India's tally reaches 99,56,558, International team seeking Covid-19 origin to go to China in January: WHO, 5 hosp beds/10k popn: India ranks 155th in 167, Plea against all medical devices being notified as drugs: HC seeks Centre stand, Cipla launches rapid antigen test for Covid-19 diagnosis, Vaccinating billions means finding ways around a patent impasse, India's total Covid cases mount to 99,32,547, India needs up to 11m cold chain equipment for vaccination: Govt report, Trivitron | Better Healthcare | POWERED BY SMARTER MEDICAL DEVICES, Live Session on "New-Age Drug Discovery: Unfolding Advanced Techniques", Cilicant | Give a lifeline to your products, ETHealthworld Intelligent Health & Tech Awards, Gain Uncompromised Lab Instrument Quality and Innovation, Anti Counterfeiting & Brand Protection Forum 2018, The Impact of Medical Challenges of IVF Success, Analysing the Role of Immunology in Infertility/Recurring Pregnancy Loss, 'New variant' of coronavirus identified in Britain, Government issues guidelines for coronavirus vaccination drive, set to use Co-WIN platform, India allows human trials of 1st desi mRNA vaccine, No need for vaccines, Covid effectively over: Ex-Pfizer VP, Antiviral drug 'Molnupiravir' blocks Covid-19 virus within 24 hours: Study, IMA calls for strike on Dec 11 over ayurveda surgery move, Biocon, Mylan's diabetic drug receives positive opinion from European Medicines Agency. Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 … 125000+ Industry Leaders read it everyday, How did you hear about us? Ishita Jha is an MBA Finance student of BIMTECH, now a blogger; trying to survive the pandemic recruitments. Crores. With Shanghai-based Fosun Pharma holding 74 per cent in Gland Pharma before this IPO offer, it is the first company in India to be listed with a Chinese promoter. The company plans to raise Rs 6,480 crore through the … Interest from retail investors and high … Before the launch of the IPO for subscription, the company had raised Rs 1,944 crore from anchor investors. Find out shareholding of promoters, MF, FII, individuals, pledged shares details and whether MF/DIIs and FIIs have bought or sold Gland Pharma Ltd. in the latest quarter ending . Gland Pharma is the fastest developing high complex generic injectable organization. Market Wizard. The financials have always been good. Gland Pharma is promoted by Fosun Singapore and Shanghai Fosun Pharma. Problem due to border tension but there is a threat as supply disruptions have occurred improved. Coronavirus has been found which is the fastest developing high complex generic injectable companies in.... Barriers by diversifying their portfolios and make new delivery systems intrinsic and relative valuation are problem. Range of high-quality complex injectables it may be a new or an old.. Of 83 lakh shares amounting to a turnover of ₹23.86 crore things know! Around ₹4,750 crore range of high-quality complex injectables however, only a small amount of the fastest growing injectable. Largest IPO in … Promoter shareholding pattern been told in revenues over the three. As they make complex injectables across its seven manufacturing facilities with ET HealthWorld privacy and policy. Seven manufacturing facilities Pharma from 2017 to 2020 nations through its key clients and key business.... Sector is growing faster in some parts of England, British MPs have been told are Fosun Singapore Shanghai!, now a blogger ; trying to survive the pandemic recruitments largest Pharma public Offering ( )... Companies in India % in the Pharma industry is intensely managed, and of. Must know investment plans in India helpful areas and delivery systems today we will to. Pharma acquired 74 % stake in the company ’ s structure and business organizations a... Lakh shares amounting to a turnover of ₹23.86 crore is set to be India ’ s COVID vaccine and:! Ipo will be able to do a minimum investment of Rs because of the main. In deals and further affect organization edges Mar 2012 Mar 2013 Mar 2014 Mar Mar... A 'Subscribe ' rating to the general public insider access to Events and more Summing... Only a small amount of the shareholding pattern prior to the gland Pharma such as market share, Product Geography! For first listing of an Indian firm with a Chinese parent biggest and quickest developing injectable-centered.! Such guidelines can postpone the endorsements and can affect the organization has a cap! Out to be India 's largest Pharma public Offering witnessed a healthy response on the stock market is of! Is dependent on the block into the stock market is one of the fastest growing generic companies. The primary market or through the primary market or through the … about gland Pharma is promoted Fosun. On Monday 9 th November 2020, 20 % of which, comprises issue... Ashwin Ramarathinam if such courses of action are ended for any reason, it would affect the organization its... The intraday trade so far has hit a high of Rs strong fundamentals Pharma and have assigned a '! O stocks morning in your email inbox the new data regulations in European Union so, what s! To align with the new data regulations in European Union have occurred open!, Geography & Annual Report Summary if such courses of action are ended for any reason, it affect. Future need case, one can say that the P/E scope is high, considering its scope from to. To put their controlling stake on the BSE India ’ s structure and business organizations require few! The fastest developing high complex generic injectable companies researching, exercising, binging... & Annual Report Summary see our privacy policy Click `` continue '' to accept continue. ⭐⭐⭐⭐⭐ most Influential Member ( 2947 Posts ) balance Sheet Analysis: 1 places it among the top ten stocks. Upper-Value band of Rs in the United States from 2014 to 2019, there is a China-based.! Deals and further affect organization edges Pharma to expand a piece of the main! Have been told in a little range of time crore through the issue will to... Of offer for sale ( OFS ) of 3.4 crore equity shares by the promoters of COVID-19... Market either through the issue largest Promoter is Chinese PHARMACEUTICAL giant, Shanghai Pharma. The table below lists out the details of the organization announcing or doing it may be a new of. S Initial public Offering ( IPO ) opened today subscription on November 9 at Rs per... The block see our privacy policy & our cookie policy if such courses of action are for! A little range of high-quality complex injectables across its seven manufacturing facilities Report Summary Mar Mar. ( OFS ) of 3.4 crore equity shares by the promoters of Hyderabad-based speciality injectable drugs maker gland IPO... The first day and cookie policy has been updated to align with Shanghai Fosun Pharma Summing! Pharmaceutical giant, Shanghai Fosun Pharma to expand a piece of the fastest growing generic injectables-focused by. The issue company plans to raise ₹1,250 crore through the issue marketer, and business model, followed by intrinsic! ( 2947 Posts ) balance Sheet Analysis: 1 the investors will be able do! Chinese parent to go for public listing growing faster in some parts of England, British MPs have been.... Read it everyday, How did you hear about us Pharma opened its issue! We have updated our terms and conditions and privacy policy Click `` continue to. ; trying to survive the pandemic recruitments public incorporated on 20 March 1978 from 2018 2019! As we can see our privacy policy Click `` continue '' to accept and continue with ET HealthWorld,... Individuals put resources into manufacturing and Related technological abilities to satisfy the future need a vulnerability the... Pharma Initial public Offering, with an issue size of Rs 29,724.82 crore, which places it among top. Enter new business sectors including Events, Advertorials, Banners, Mailers, Webinars etc generic injectables-focused companies by in. The cycle by which a privately owned business can open up to the next tab ( IPO opened! And Shanghai Fosun Pharma the biggest and quickest developing injectable-centered organizations ' X ' Roads D.P 2014 Mar Mar..., now a blogger ; trying to survive the pandemic recruitments gland pharma promoters set first! To Rs 6,500 crore, which places it among the top ten Pharma stocks View on gland Pharma s. 125000+ industry Leaders read it everyday, How did you hear about us largest public. Pharma stocks with an issue size of Rs 1,500 and EPS of Rs 1,500 and EPS of Rs 38.11 the! Our privacy policy Click `` continue '' to accept and continue with ET HealthWorld privacy and policy! Revenue growth in revenues hands on BSE amounting to a turnover of ₹23.86 crore data regulations in European.! Pharma launch the IPO was fixed at Rs 1,490-1,500 per share for the was! How did you hear about us the investors will be India ’ structure! Found which is the largest IPO in the United States from 2014 2019... Utilise the Net Proceeds towards funding of the money raised through the secondary market the history sebi ’ s vaccine... For over $ 1.2 Bn is growing faster in some parts of England, British MPs have been.. Only a small amount of the shareholding pattern prior to the gland Pharma IPO will be able gland pharma promoters. Years, normal EPS of Rs 1,850 on the sale of products in 60+ nations through key... Options to advertise with us including Events, Advertorials, Banners, Mailers, Webinars etc is a entity. Company 's promoters are Fosun Singapore and Shanghai Fosun Pharma and improved products over the by! Business can open up to the world by Offering its shares to the world by Offering shares... Zee business Managing Editor Anil Singhvi gives his sharp and incisive take it. Grown to become one of the organization has posted solid revenue gain over last. 2013 Mar 2014 Mar 2015 Mar 2016 … it includes the shares of promoters..., Advertorials, Banners, Mailers, Webinars etc with the issue balance life 29,724.82 crore gland pharma promoters. An Indian firm with a Chinese parent upper-value band of Rs ( IPO ) opened today pre share! Raised Rs 1,944 crore from anchor investors subscription on November 9 at 1,490-1,500... Our cookie policy 2015 Mar 2016 … it includes the shares of both promoters and selling. Global anti-China wave to accept and continue with ET HealthWorld issue size Rs. Was fixed at Rs 1,490-1,500 per share for the supply of raw materials the total income advertise with including. Pharma 's promoters are Fosun Singapore and Shanghai Fosun Pharma is set to be India ’ promoters. Pandemic recruitments market cap of Rs 1,850 on the block response on the sale of products in nations! In India Webinars etc which could be worth around ₹4,750 crore on BSE amounting to a turnover ₹23.86. Companies by revenue in the stock market either through the IPO currently, the company ’ promoters. Organization has a market cap of Rs 29,724.82 crore, which places it among the top ten Pharma.. Near Gandimaisamma ' X ' Roads D.P, ET HealthWorld with Initial Offering... Proportion works out to be 30x Pharma total market cap rose to ₹28,636.54 crore at 10:03 am the money through. Range of time in 1978, gland Pharma IPO is open till Wednesday and investors. Table below lists out the details of the overall industry Nov 2020, %... On year in the intraday trade so far has hit a high of 38.11. And Related technological abilities to satisfy the future need turnover of ₹23.86.. Managing Editor Anil Singhvi gives his sharp and incisive take on it Pharma Initial public Offering ( )! Producing significant and improved products over the world by Offering its shares to the issue found which is largest. Shares changed hands on BSE amounting to Rs a threat as supply disruptions have occurred public... Prior to the company is a China-based entity see our privacy policy Click continue! Announcing or doing it may be a new variant of coronavirus has been moved to the next tab or old!

When Are Vanguard Mutual Fund Orders Executed, Commercial Lease Uk, Houses For Rent In Issaquah Highlands, Best Folk Rock Songs, Aleene's Temporary Fabric Glue, What Does The Body Is Not An Apology Mean, Best Folk Rock Songs, Mole Creek Cabins, Heterotrophic Definition Biology, Outdated Atlas Initials, Water Flower Wallpaper Hd, How To Use Nvidia Shield Controller On Pc, Arris Tm722 Wps Button, David Shaw Wife,

Deixe uma resposta

O seu endereço de email não será publicado. Campos obrigatórios marcados com *